APA (7th ed.) Citation

Ghilardi, G., Chong, E., Svoboda, J., Wohlfarth, P., Nasta, S., Williamson, S., . . . Napier, E. (2022). Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Annals of Oncology, 33(9), 916. https://doi.org/10.1016/j.annonc.2022.05.521

Chicago Style (17th ed.) Citation

Ghilardi, G., et al. "Bendamustine Is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-cell Lymphomas." Annals of Oncology 33, no. 9 (2022): 916. https://doi.org/10.1016/j.annonc.2022.05.521.

MLA (9th ed.) Citation

Ghilardi, G., et al. "Bendamustine Is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-cell Lymphomas." Annals of Oncology, vol. 33, no. 9, 2022, p. 916, https://doi.org/10.1016/j.annonc.2022.05.521.